A Novel Target for the Neutralization of Cancer Stem Cells in Glioblastoma

Tech ID: 29238 / UC Case 2017-888-0

Brief Description

Researchers at UC Irvine have recently discovered a novel mechanism that can be exploited to disrupt the maintenance and self-renewal capacity of cancer stem cells. This finding has therapeutic implications for the treatment of Glioblastoma Multiforme (GBM), which is the most common, aggressive and lethal primary brain tumor.

Full Description

Glioblastoma (GBM) is the most common, aggressive, and lethal primary brain tumor in adults. Currently, only four drugs are approved for GBM treatment. The current standard of care drug for GBM, Temozolomide, provides a limited survival advantage of less than 3 months, even when with combined surgical and radiation therapies. Furthermore, standard therapy is highly toxic to healthy cells. In GBM, cancer stem cells are associated with chemotherapy resistance and tumor recurrence. The increased proliferation of the cancer stem cell population is a prognostic marker for disease progression and poor clinical outcome; however, few therapeutic strategies target cancer stem cell self-renewal. UCI scientists have discovered a novel mechanism that can be exploited to regulate cancer stem maintenance and renewal to treat GBM, and may provide a promising approach to increase the overall efficacy of GBM treatment modalities.

Suggested uses

· Targeting cancer stem cells to increase efficacy of GBM treatment

Advantages

  • May increase efficacy of GBM treatments
  • Non-toxic to healthy cells; reduces comorbidities
  • Targets slow-dividing stem cells as opposed to rapid-dividing cells (i.e. chemotherapies)

Patent Status

Patent Pending

State Of Development

· Ongoing and future plans include:

o Development of a neutralizing antibody to target cancer stem cell renewal in vivo

o Test efficacy of combined neutralizing antibody with Temozolomide

o Evaluation of therapeutic candidate in vitro and in vivo

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Categorized As

  • AN INTEGRAL PART OF
  • Institute for Innovation Logo
  • Institute for Innovation Logo

University of California, Irvine Invention Transfer Group
5141 California Avenue, Suite 200, Irvine,CA 92697-7700
Tel: 949.824.2683 | Fax: 949.824.3880
www.ota.uci.edu | ota@uci.edu

© 2018, The Regents of the University of California
Terms of use | Privacy Notice